Navigation Links
3SBio Announces Conversion of Isotechnika Debenture
Date:11/18/2010

SHENYANG, China, Nov. 18, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio") (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products today announced that it has recently converted the remaining US$2.58 million of a US$4.5 million debenture convertible into Isotechnika Pharma Inc. ("Isotechnika") common shares issued on August 23, 2010. As a result, Isotechnika issued an additional 17,516,000 common shares at C$0.155 per common share to 3SBio. The common shares are subject to a four month plus one day hold which commenced on August 23, 2010.  Prior to this conversion, 3SBio owned 13,000,000 common shares of Isotechnika. The US$4.5 million debenture has now been fully converted and 3SBio owns approximately 18.83% of the issued and outstanding shares of Isotechnika.

The debenture was acquired in conjunction with the strategic partnership with Isotechnika to develop and commercialize voclosporin in China announced on August 24, 2010. 3SBio will continually review its investment alternatives and may purchase or sell securities of Isotechnika from time to time in accordance with applicable securities laws.

3SBio has also filed a report with the Canadian regulatory authorities containing additional information (the "Early Warning Report").  A copy of the Early Warning Report will appear with Isotechnika's documents on the SEDAR website, at www.sedar.com and may also be obtained by contacting the persons listed below.  

About 3SBio Inc.3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 500 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX".  3SBio's address is No. 3 A1, Road 10, Shenyang Economy & Technology Development Zone, Shenyang, China 110027. Please see www.3SBio.com for more information. Investor Contacts  Bo TanChief Financial Officer3SBio Inc.Tel: + 86 24 2581-1820 ir@3SBio.comTom FolinsbeeDirector of Investor Relations3SBio Inc. Tel: + 852 8191-6991ir@3SBio.com
'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
2. 3SBio Announces Partial Conversion of Isotechnika Debenture
3. 3SBio Announces Investor Conference Schedule
4. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
5. 3SBio Inc. Announces Results of Annual General Meeting
6. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
7. Medivir Announces Positive 24-week Interim Data of TMC435 From the ASPIRE Study (C206)
8. GSI Group Inc. Announces John Roush to Become Chief Executive Officer
9. Hanger Orthopedic Group, Inc. Announces Expiration of Offer to Purchase Outstanding 10 1/4% Senior Notes Due 2014
10. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
11. MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):